home / stock / lci / lci news


LCI News and Press, Lannett Co Inc From 02/01/23

Stock Information

Company Name: Lannett Co Inc
Stock Symbol: LCI
Market: NYSE

Menu

LCI LCI Quote LCI Short LCI News LCI Articles LCI Message Board
Get LCI Alerts

News, Short Squeeze, Breakout and More Instantly...

LCI - LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE

LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE PR Newswire Q2 Business and Financial Highlights: Net Sales were $80.9 Million Gross Margin was 18%, Adjusted Gross Margin was 19% Net Sales, Gross Ma...

LCI - Lannett announces 1-for-4 reverse stock split

Lannett ( NYSE: LCI ) said its board approved a 1-for-4 reverse stock split of its issued and outstanding shares, which will be effective at 5 p.m. Eastern Time on February 6. No fractional shares will be issued in connection with the reverse stock split, the company said. F...

LCI - LANNETT ANNOUNCES 1 FOR 4 REVERSE STOCK SPLIT

LANNETT ANNOUNCES 1 FOR 4 REVERSE STOCK SPLIT PR Newswire TREVOSE, Pa. , Jan. 25, 2023 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that its Board of Directors approved a 1-for-4 reverse stock split of its issued and outstanding shares of com...

LCI - LANNETT TO REPORT FISCAL 2023 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, FEBRUARY 1

LANNETT TO REPORT FISCAL 2023 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, FEBRUARY 1 PR Newswire TREVOSE, Pa. , Jan. 25, 2023 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its ...

LCI - LANNETT PROVIDES DEVELOPMENT UPDATE ON BIOSIMILAR INSULIN PRODUCTS

LANNETT PROVIDES DEVELOPMENT UPDATE ON BIOSIMILAR INSULIN PRODUCTS PR Newswire --Announces Positive Animal PK Study Results of Insulin Aspart Versus US NovoLog ® -- --Analysis of Pivotal Trial Results of Insulin Glargine Nearly Completed, BLA Fil...

LCI - Lannett gains on patent deal for biosimilar insulin device

The shares of generic drugmaker Lannett Company ( NYSE: LCI ) added ~9% on Monday after announcing a licensing deal for patents related to a pen injector device for its investigational biosimilar insulin glargine and biosimilar insulin aspart products. Per the terms, L...

LCI - LANNETT ANNOUNCES PATENT LICENSES FOR THE PEN INJECTOR DELIVERY DEVICE TO BE USED FOR ITS INSULIN GLARGINE AND INSULIN ASPART DEVELOPMENT PROGRAM

LANNETT ANNOUNCES PATENT LICENSES FOR THE PEN INJECTOR DELIVERY DEVICE TO BE USED FOR ITS INSULIN GLARGINE AND INSULIN ASPART DEVELOPMENT PROGRAM PR Newswire TREVOSE, Pa. , Nov. 7, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced tha...

LCI - Lannett Company, Inc. (LCI) Q1 2023 Earnings Call Transcript

Lannett Company, Inc. (LCI) Q1 2023 Earnings Conference Call November 02, 2022 04:30 PM ET Company Participants Robert Jaffe - Investor Relations Tim Crew - Chief Executive Officer John Kozlowski - Chief Financial Officer Conference Call Participants ...

LCI - Lannett Non-GAAP EPS of -$0.42 beats by $0.04, revenue of $75.1M beats by $6.88M

Lannett press release ( NYSE: LCI ): Q1 Non-GAAP EPS of -$0.42 beats by $0.04 . Revenue of $75.1M (-26.0% Y/Y) beats by $6.88M . Shares +4.4% . Gross Margin 17%, Adjusted Gross Margin 18% Net Sales, Gross Margin and Adjusted Gross Margin Increased f...

LCI - LANNETT REPORTS BETTER THAN EXPECTED FINANCIAL RESULTS FOR FISCAL 2023 FIRST-QUARTER; REITERATES FULL-YEAR GUIDANCE

LANNETT REPORTS BETTER THAN EXPECTED FINANCIAL RESULTS FOR FISCAL 2023 FIRST-QUARTER; REITERATES FULL-YEAR GUIDANCE PR Newswire Q1 Business and Financial Highlights: Net Sales were $75.1 Million Gross Margin 17%, Adjusted Gross Margin 18% ...

Previous 10 Next 10